Eric Blasius Risser - 04 Mar 2024 Form 4 Insider Report for MACROGENICS INC (MGNX)

Role
Chief Operating Officer
Signature
/s/ Lynn M. Cilinski, Attorney-in-fact
Issuer symbol
MGNX
Transactions as of
04 Mar 2024
Net transactions value
-$661,251
Form type
4
Filing time
06 Mar 2024, 16:20:36 UTC
Previous filing
20 Feb 2024
Next filing
11 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MGNX Common Stock Options Exercise $152,250 +15,000 +23% $10.15 80,059 04 Mar 2024 Direct
transaction MGNX Common Stock Sale $300,000 -15,000 -19% $20.00 65,059 04 Mar 2024 Direct F1
transaction MGNX Common Stock Sale $513,501 -26,159 -40% $19.63 38,900 04 Mar 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGNX Employee stock option (right to buy) Options Exercise $0 -15,000 -8.8% $0.000000 155,000 04 Mar 2024 Common Stock 15,000 $10.15 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/21/2022.
F2 This transaction was executed in multiple trades at prices ranging from $19.50 to $19.78. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.